Abvc Biopharma, INC 8-K filings

ABVC BioPharma has postponed its previously announced distribution of BioKey (Cayman), Inc. ordinary shares from August 3, 2026, to August 21, 2026, to finalize administrative, regulatory, and tax matters.

ABVC BioPharma, Inc. has dismissed Simon & Edward, LLP and engaged Kreit & Chiu CPA LLP as its new independent registered public accounting firm.

ABVC BioPharma, Inc. shareholders re-elected all 11 directors, ratified the auditor, and approved an increase to the equity incentive plan at their 2026 annual meeting.

ABVC BioPharma, Inc. filed an amendment detailing additional unregistered sales of 1.5 million common shares, raising $2.28 million, with purchasers transferring voting rights to the chairman.

ABVC BioPharma announced strong Q3 2025 financial results, including a 230% year-over-year increase in licensing revenue and significant asset expansion.

ABVC BioPharma's Board approved a new performance incentive plan for directors and officers, contingent on achieving a $1 billion market cap by December 2027.

ABVC BioPharma discloses that its former independent auditor, WWC, P.C., has refused to provide a letter to the SEC regarding its non-renewal of engagement.

ABVC BioPharma announced significant asset growth and a narrowed diluted loss per share for Q2 2025, alongside strategic land acquisition and post-quarter licensing revenue.

ABVC BioPharma, Inc. has finalized a definitive agreement to acquire land in Taiwan from director Shuling Jiang for approximately $3.36 million, paid in common stock and warrants, alongside a new consulting agreement.

ABVC BioPharma, Inc. announced the results of its 2025 annual meeting, where shareholders re-elected all directors, ratified its auditor, and approved a significant related-party land acquisition and an expansion of its equity incentive plan.

ABVC BioPharma, Inc. has filed an amendment to its current report, disclosing additional unregistered sales of common stock totaling $670,000, bringing the total capital raised through these offerings to approximately $1.29 million.

ABVC BioPharma sold unregistered shares of common stock to non-U.S. persons in two offerings, raising a total of approximately $619,625.

ABVC BioPharma announces it has regained compliance with Nasdaq's minimum bid price rule, highlighting significant improvements in revenue, operating expenses, and EPS.

ABVC BioPharma has been notified by Nasdaq that it is back in compliance with listing rules after demonstrating an increase in stockholders' equity.

ABVC BioPharma clarifies its stance on previously issued financial statements, stating that an amendment to the 2023 Annual Report is no longer required due to corrections made in the 2024 Form 10-K.

ABVC BioPharma announces improved financial results for Q1 2025 and unveils plans for an AI-enabled agricultural facility in Taiwan.

ABVC BioPharma is at risk of being delisted from the Nasdaq Capital Market due to not meeting the minimum stockholders' equity requirement, and has received notification from Nasdaq to submit a plan to regain compliance.

ABVC BioPharma reports significant financial improvements in 2024, including a 234% revenue increase and a 21% reduction in operating expenses, driven by global licensing milestones.

ABVC BioPharma reports significant financial improvements in 2024, driven by revenue growth and cost reductions, but restates prior financials due to accounting errors.

Leeds Chow resigned as CFO of ABVC BioPharma, effective March 5, 2025, with CEO Uttam Patil stepping in as interim CFO.

ABVC BioPharma receives a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share.

ABVC BioPharma has entered into a third letter agreement with Lind Global Fund II, resulting in the exercise of warrants for $411,666.80 and a 15-day restriction on further share issuance.

ABVC BioPharma reports its first operational profit in Q3 2024, alongside significant revenue growth and advancements in clinical development.

ABVC BioPharma has entered into an agreement with Lind Global Fund II, LP, resulting in the exercise of warrants for 500,000 shares at a reduced price, generating additional capital for the company.

ABVC BioPharma has appointed Simon & Edward, LLP as its new independent auditor after WWC, P.C. decided not to renew its engagement.

ABVC Biopharma has received notification from Nasdaq that it has regained compliance with Shareholder Approval Rules for continued listing.

ABVC BioPharma updated its corporate presentation, showcasing significant revenue growth, improved earnings per share, and advancements in its clinical pipeline, including key licensing agreements.

ABVC BioPharma announced strong Q2 2024 financial results, highlighted by significant licensing agreements, improved earnings per share, and revenue growth.

ABVC BioPharma's CFO has suspended his duties due to a salary dispute, and the company has corrected figures in a previous press release regarding potential licensing fees.

ABVC BioPharma has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement of $1.00 for 30 consecutive days, placing it at risk of delisting.